Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49858 | 0.93 | CYP3A4 (0.52) | CYP3A4TDP1DRD1ACHETSHR | |
| Hydrochloric Acid SCHEMBL11571801 | 0.91 | CYP3A4 (0.50) | CYP3A4TDP1DRD1ACHETSHR | |
| Iodide SCHEMBL30903480 | 0.91 | CYP3A4 (0.50) | CYP3A4TDP1DRD1ACHETSHR | |
| SCHEMBL31531976 | 0.91 | CYP3A4 (0.50) | CYP3A4TDP1DRD1ACHETSHR | |
| Hydrochloric Acid SCHEMBL31198728 | 0.91 | CYP3A4 (0.50) | CYP3A4TDP1DRD1ACHETSHR | |
| Bromide SCHEMBL30317742 | 0.91 | CYP3A4 (0.50) | CYP3A4TDP1DRD1ACHETSHR | |
| SCHEMBL31532278 | 0.91 | CYP3A4 (0.50) | CYP3A4TDP1DRD1ACHETSHR | |
| Iodide SCHEMBL31531977 | 0.89 | CYP3A4 (0.48) | CYP3A4TDP1DRD1ACHETSHR | |
| SCHEMBL16018463 | 0.89 | CYP3A4 (0.48) | CYP3A4TDP1DRD1ACHETSHR | |
| SCHEMBL29535212 | 0.89 | CYP3A4 (0.52) | CYP3A4TDP1DRD1ACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222009-A1 | DINUCLEAR GOLD(I) COMPLEXES FOR TREATING CANCER | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-07-10 | — | — | US | disclosed |
| US-20250057959-A1 | PHOSPHANE GOLD(I)-N-HETEROCYCLIC CARBENE COMPLEXES FOR TREATING CANCER | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-02-20 | — | — | US | disclosed |
| US-20250041427-A1 | DINUCLEAR PHOSPHANE GOLD(I) COMPLEXES FOR TREATING CANCER | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-02-06 | — | — | US | disclosed |
| US-10301335-B2 | Gold complex-containing cancer activity composition | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-05-28 | — | — | US | disclosed |
| US-10294254-B2 | DNA/Dithiocarbamato phosphine metal complex | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-05-21 | — | — | US | disclosed |
| US-10280187-B2 | Mononucleotide-dithiocarbamate complex | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-05-07 | — | — | US | disclosed |
| US-10273257-B2 | Cancer cell-containing composition | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-04-30 | — | — | US | disclosed |
| US-20190040089-A1 | GOLD COMPLEX-CONTAINING CANCER ACTIVITY COMPOSITION | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-02-07 | — | — | US | disclosed |
| US-20180362555-A1 | MONONUCLEOTIDE-DITHIOCARBAMATE COMPLEX | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-20 | — | — | US | disclosed |
| US-20180362557-A1 | CANCER CELL-CONTAINING COMPOSITION | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-20 | — | — | US | disclosed |
| US-20180362556-A1 | DNA/DITHIOCARBAMATO PHOSPHINE METAL COMPLEX | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-20 | — | — | US | disclosed |
| US-10144749-B2 | Gold complexes of alkylated phosphines | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-04 | — | — | US | disclosed |
| US-20180273559-A1 | GOLD COMPLEXES OF ALKYLATED PHOSPHINES | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-09-27 | — | — | US | disclosed |
| US-20180273558-A1 | COMPOSITION CONTAINING A GOLD (I) COMPLEX AND CANCER CELLS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-09-27 | — | — | US | disclosed |
| US-10077280-B2 | Mixed ligand gold(I) complexes as anti-cancer agents | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-09-18 | — | — | US | disclosed |
| US-20170305942-A1 | MIXED LIGAND GOLD(I) COMPLEXES AS ANTI-CANCER AGENTS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222009-A1 | DINUCLEAR GOLD(I) COMPLEXES FOR TREATING CANCER | PDCD1, PDCD5, PDCD1LG2 | CYP3A4 4205/4885TDP1 1708/4885DRD1 1595/4885 |
| US-10280187-B2 | Mononucleotide-dithiocarbamate complex | NCL, POLN, NTPCR | CYP3A4 4749/4885TDP1 903/4885DRD1 3354/4885 |
| US-20180362555-A1 | MONONUCLEOTIDE-DITHIOCARBAMATE COMPLEX | NCL, POLN, NTPCR | CYP3A4 4749/4885TDP1 903/4885DRD1 3354/4885 |
| US-10077280-B2 | Mixed ligand gold(I) complexes as anti-cancer agents | TP53, ACP3, PHOSPHO1 | CYP3A4 4497/4885TDP1 923/4885DRD1 3925/4885 |
| US-10294254-B2 | DNA/Dithiocarbamato phosphine metal complex | POLRMT, TP53, TOP1 | CYP3A4 4422/4885TDP1 75/4885DRD1 2469/4885 |
| US-10301335-B2 | Gold complex-containing cancer activity composition | AP3B1, PHOSPHO1, AP3M1 | CYP3A4 3749/4885TDP1 569/4885DRD1 3686/4885 |
| US-20180273559-A1 | GOLD COMPLEXES OF ALKYLATED PHOSPHINES | PHOSPHO1, TP53, GOPC | CYP3A4 3971/4885TDP1 751/4885DRD1 2932/4885 |
| US-20180362557-A1 | CANCER CELL-CONTAINING COMPOSITION | PHOSPHO1, TP53, MCL1 | CYP3A4 4650/4885TDP1 1122/4885DRD1 4344/4885 |
| US-20180273558-A1 | COMPOSITION CONTAINING A GOLD (I) COMPLEX AND CANCER CELLS | TP53, PHOSPHO1, CALU | CYP3A4 4407/4885TDP1 811/4885DRD1 4051/4885 |
| US-20180362556-A1 | DNA/DITHIOCARBAMATO PHOSPHINE METAL COMPLEX | POLRMT, TP53, TOP1 | CYP3A4 4422/4885TDP1 75/4885DRD1 2469/4885 |
| US-10273257-B2 | Cancer cell-containing composition | PHOSPHO1, TP53, MCL1 | CYP3A4 4650/4885TDP1 1122/4885DRD1 4344/4885 |
| US-20190040089-A1 | GOLD COMPLEX-CONTAINING CANCER ACTIVITY COMPOSITION | AP3B1, PHOSPHO1, AP3M1 | CYP3A4 3749/4885TDP1 569/4885DRD1 3686/4885 |
| US-10144749-B2 | Gold complexes of alkylated phosphines | PHOSPHO1, TP53, GOPC | CYP3A4 3971/4885TDP1 751/4885DRD1 2932/4885 |
| US-20170305942-A1 | MIXED LIGAND GOLD(I) COMPLEXES AS ANTI-CANCER AGENTS | TP53, ACP3, PHOSPHO1 | CYP3A4 4497/4885TDP1 923/4885DRD1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.